409 related articles for article (PubMed ID: 24844925)
1. Three levels face centered central composite design of colon targeted micro-particulates system of celecoxib: screening of formulations variables and in vivo studies.
Nandy BC; Verma V; Dey S; Mazumder B
Curr Drug Deliv; 2014; 11(5):621-35. PubMed ID: 24844925
[TBL] [Abstract][Full Text] [Related]
2. Formulation and characterizations of delayed release multi particulates system of indomethacin: optimization by response surface methodology.
Nandy BC; Mazumder B
Curr Drug Deliv; 2014; 11(1):72-86. PubMed ID: 24783236
[TBL] [Abstract][Full Text] [Related]
3. Quality by design approach for developing chitosan-Ca-alginate microspheres for colon delivery of celecoxib-hydroxypropyl-β-cyclodextrin-PVP complex.
Mennini N; Furlanetto S; Cirri M; Mura P
Eur J Pharm Biopharm; 2012 Jan; 80(1):67-75. PubMed ID: 21864681
[TBL] [Abstract][Full Text] [Related]
4. Effect of formulation variables on preparation of celecoxib loaded polylactide-co-glycolide nanoparticles.
Cooper DL; Harirforoosh S
PLoS One; 2014; 9(12):e113558. PubMed ID: 25502102
[TBL] [Abstract][Full Text] [Related]
5. Colon-targeted celecoxib-loaded Eudragit® S100-coated poly-ε-caprolactone microparticles: preparation, characterization and in vivo evaluation in rats.
Ghorab DM; Amin MM; Khowessah OM; Tadros MI
Drug Deliv; 2011; 18(7):523-35. PubMed ID: 21793779
[TBL] [Abstract][Full Text] [Related]
6. Development and evaluation of a gastroretentive drug delivery system for the low-absorption-window drug celecoxib.
Ali J; Tyagi P; Ahuja A; Baboota S; Hasan S
PDA J Pharm Sci Technol; 2007; 61(2):88-96. PubMed ID: 17479716
[TBL] [Abstract][Full Text] [Related]
7. Formulation and evaluation of chitosan microspheres of aceclofenac for colon-targeted drug delivery.
Umadevi SK; Thiruganesh R; Suresh S; Reddy KB
Biopharm Drug Dispos; 2010 Oct; 31(7):407-27. PubMed ID: 20848388
[TBL] [Abstract][Full Text] [Related]
8. Studies on the development of colon-targeted delivery systems for celecoxib in the prevention of colorectal cancer.
Krishnaiah YS; Satyanarayana V; Kumar BD; Karthikeyan RS
J Drug Target; 2002 May; 10(3):247-54. PubMed ID: 12075826
[TBL] [Abstract][Full Text] [Related]
9. Bumadizone calcium dihydrate microspheres compressed tablets for colon targeting: formulation, optimization and in vivo evaluation in rabbits.
Nour SA; Abdelmalak NS; Naguib MJ
Drug Deliv; 2015 May; 22(3):286-97. PubMed ID: 24601826
[TBL] [Abstract][Full Text] [Related]
10. Lappaconitine-loaded microspheres for parenteral sustained release: effects of formulation variables and in vitro characterization.
Xu H; Zhong H; Liu M; Xu C; Gao Y
Pharmazie; 2011 Sep; 66(9):654-61. PubMed ID: 22026119
[TBL] [Abstract][Full Text] [Related]
11. Celecoxib incorporated chitosan microspheres: in vitro and in vivo evaluation.
Thakkar H; Sharma RK; Mishra AK; Chuttani K; Murthy RS
J Drug Target; 2004; 12(9-10):549-57. PubMed ID: 15621680
[TBL] [Abstract][Full Text] [Related]
12. Microspheres with pH modulated release: design and characterization of formulation variables for colonic delivery.
Chandran S; Sanjay KS; Ali Asghar LF
J Microencapsul; 2009 Aug; 26(5):420-31. PubMed ID: 18821120
[TBL] [Abstract][Full Text] [Related]
13. Influence of selected formulation variables on the preparation of enzyme-entrapped Eudragit S100 microspheres.
Rawat M; Saraf S; Saraf S
AAPS PharmSciTech; 2007 Dec; 8(4):E116. PubMed ID: 18181537
[TBL] [Abstract][Full Text] [Related]
14. Formulation Optimization of Human Insulin Loaded Microspheres for Controlled Oral Delivery Using Response Surface Methodology.
Agrawal G; Wakte P; Shelke S
Endocr Metab Immune Disord Drug Targets; 2017; 17(2):149-165. PubMed ID: 28472911
[TBL] [Abstract][Full Text] [Related]
15. Design, development and evaluation of novel nanoemulsion formulations for transdermal potential of celecoxib.
Baboota S; Shakeel F; Ahuja A; Ali J; Shafiq S
Acta Pharm; 2007 Sep; 57(3):315-32. PubMed ID: 17878111
[TBL] [Abstract][Full Text] [Related]
16. Nanoemulsion: a promising tool for solubility and dissolution enhancement of celecoxib.
Shakeel F; Faisal MS
Pharm Dev Technol; 2010; 15(1):53-6. PubMed ID: 19552546
[TBL] [Abstract][Full Text] [Related]
17. Niosomal gel for site-specific sustained delivery of anti-arthritic drug: in vitro-in vivo evaluation.
Kaur K; Jain S; Sapra B; Tiwary AK
Curr Drug Deliv; 2007 Oct; 4(4):276-82. PubMed ID: 17979648
[TBL] [Abstract][Full Text] [Related]
18. Influence of polymers on the bioavailability of microencapsulated celecoxib.
Homar M; Ubrich N; El Ghazouani F; Kristl J; Kerc J; Maincent P
J Microencapsul; 2007 Nov; 24(7):621-33. PubMed ID: 17763056
[TBL] [Abstract][Full Text] [Related]
19. Response surface methodology to obtain beta-estradiol biodegradable microspheres for long-term therapy of osteoporosis.
Zaghloul AA; Mustafa F; Siddiqui A; Khan M
Pharm Dev Technol; 2006; 11(3):377-87. PubMed ID: 16895848
[TBL] [Abstract][Full Text] [Related]
20. Microbeads: a novel multiparticulate drug delivery technology for increasing the solubility and dissolution of celecoxib.
McDonald BF; Coulter IS; Marison IW
Pharm Dev Technol; 2015 Mar; 20(2):211-8. PubMed ID: 24283499
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
